Zheng Li

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 9

Top Topics

Acute Myeloid Leukemia

Newly Diagnosed

Top Venues

Blood cancer journal

This page only lists publications with an associated author ORCID identifier.

Publications

Chao-Ling Wan, Yu-Qing Liu, Fang-Tong Liu, Yuan-Hong Huang, Han-Yu Cao, Si-Man Huang, Kai-Wen Tan, Shuai-Shuai Ge, Miao Wang, Mei-Jing Liu, Zi-Hao Wang, Zheng Li, Sheng-Li Xue, Hai-Ping Dai
Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification. Blood cancer journal 14 (1) (2024)
Chao-Ling Wan, Yu-Qing Liu, Fang-Tong Liu, Yuan-Hong Huang, Han-Yu Cao, Si-Man Huang, Kai-Wen Tan, Shuai-Shuai Ge, Miao Wang, Mei-Jing Liu, Zi-Hao Wang, Zheng Li, Sheng-Li Xue, Hai-Ping Dai
Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification. Blood cancer journal 14 (1) (2024)
Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)
Miao Wang, Han-Yu Cao, Kai-Wen Tan, Qiao-Cheng Qiu, Yuan-Hong Huang, Shuai-Shuai Ge, Zi-Hao Wang, Jia Chen, Xiao-Wen Tang, De-Pei Wu, Sheng-Li Xue, Zheng Li, Hai-Ping Dai
Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study. Blood cancer journal 13 (1) (2023)
Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)
Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)
Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)
Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)
Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)